Nasdaq · CIK 0001374339
PMN ProMIS Neurosciences Inc.
Insider trading from SEC Form 4. Last filing 7 d ago. Close $9.61 on Oct 9, 2026, +42% from the 52-week low and -61% from the high.
ProMIS Neurosciences Inc. (PMN) has 37 SEC Form 4 filings on file from 13 insiders, the latest filed on Oct 6, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
6 open-market trades have been scored at PMN. The newest: Eugene Williams (director) bought $49k of stock on Mar 5, 2026, filed Mar 6, 2026, scored 38 (weak). The largest of the 6 shown: Slanix Paul Alex (director) bought $8.5M on Feb 3, 2026, scored 58 (moderate). 2 insiders bought within 14 days of each other around Mar 5, 2026.
PMN closed at $9.61 on Oct 9, 2026, 42% above its 52-week low and 61% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at ProMIS Neurosciences Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 38Weak | Eugene Williams director buy | $49k 2,000 shares | +19% | +267% from low-11% from high | |
| 46Moderate | Eugene Williams director buy | $92k 4,000 shares | +63% | +237% from low-19% from high | |
| 46Moderate | Johanne Kaplan Chief Development Officer buy | $25k 1,629 shares | +70% | +139% from low-42% from high | |
| 58Moderate | Slanix Paul Alex director buy | $8.5M 700,741 shares | +289% | +135% from low-43% from high | |
| 26Weak | Max A. Milbury Principal Accounting Officer buy | $15k 30,392 shares | +203% | +28% from low-61% from high | |
| 25Weak | Neil Cashman Chief Scientific Officer buy | $15k 15,000 shares | +928% | - |
Transactions
The newest 50 of 74 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | Ivana Rubino Chief Commercial Officer | AGrant or award Option (right to buy)derivative | +80,000 | $0.00 | $0 | 80,000 | 7 d ago |
| May 20, 2026 | Neil Cashman Chief Scientific Officer | AGrant or award Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | May 22, 2026 |
| May 20, 2026 | Slanix Paul Alex director | AGrant or award Option (right to buy)derivative | +5,500 | $0.00 | $0 | 5,500 | May 22, 2026 |
| May 20, 2026 | Slanix Paul Alex director | AGrant or award Option (right to buy)derivative | +11,000 | $0.00 | $0 | 11,000 | May 22, 2026 |
| Mar 5, 2026 | Eugene Williams director | POpen-market purchase Common Shares | +2,000 | $24.40 | $49k | 12,397 | Mar 6, 2026 |
| Mar 2, 2026 | Eugene Williams director | POpen-market purchase Common Shares | +1,000 | $22.53 | $23k | 7,397 | Mar 4, 2026 |
| Mar 3, 2026 | Eugene Williams director | POpen-market purchase Common Shares | +1,000 | $21.89 | $22k | 8,397 | Mar 4, 2026 |
| Mar 4, 2026 | Eugene Williams director | POpen-market purchase Common Shares | +2,000 | $24.00 | $48k | 10,397 | Mar 4, 2026 |
| Feb 19, 2026 | Johanne Kaplan Chief Development Officer | POpen-market purchase Common Shares | +1,629 | $15.35 | $25k | 3,941 | Feb 23, 2026 |
| Feb 3, 2026 | Patrick D. Kirwin director | AGrant or award Common Shares | +3,050 | $12.13 | $37k | 5,135 | Feb 5, 2026 |
| Feb 3, 2026 | Max A. Milbury Principal Accounting Officer | AGrant or award Common Shares | +6,595 | $12.13 | $80k | 8,409 | Feb 5, 2026 |
| Feb 3, 2026 | Neil K Warma Chief Executive Officer | AGrant or award Common Shares | +6,183 | $12.13 | $75k | 6,183 | Feb 5, 2026 |
| Feb 3, 2026 | Slanix Paul Alex director | POpen-market purchase Common Sharesindirect: See Footnote | +700,741 | $12.13 | $8.5M | 943,090 | Feb 5, 2026 |
| Feb 3, 2026 | Neil Cashman Chief Scientific Officer | AGrant or award Common Sharesindirect: By Research Capital Corporation | +4,122 | $12.13 | $50k | 4,122 | Feb 5, 2026 |
| Feb 3, 2026 | Johanne Kaplan Chief Development Officer | AGrant or award Common Shares | +2,060 | $12.13 | $25k | 2,312 | Feb 5, 2026 |
| Feb 3, 2026 | Max A. Milbury Principal Accounting Officer | AGrant or award Warrants to purchase Common Sharesderivative | +6,595 | - | - | 6,595 | Feb 5, 2026 |
| Feb 3, 2026 | Neil K Warma Chief Executive Officer | AGrant or award Warrants to purchase Common Sharesderivative | +6,183 | - | - | 6,183 | Feb 5, 2026 |
| Feb 3, 2026 | Slanix Paul Alex director | POpen-market purchase Warrantsderivativeindirect: See Footnote | +700,741 | - | - | 700,741 | Feb 5, 2026 |
| Feb 3, 2026 | Johanne Kaplan Chief Development Officer | AGrant or award Warrants to purchase Common Sharesderivative | +2,060 | - | - | 2,060 | Feb 5, 2026 |
| Feb 3, 2026 | Patrick D. Kirwin director | AGrant or award Warrants to purchase Common Sharesderivative | +3,050 | - | - | 3,050 | Feb 5, 2026 |
| Feb 3, 2026 | Neil Cashman Chief Scientific Officer | AGrant or award Warrants to purchase Common Sharesderivativeindirect: By Research Capital Corporation | +4,122 | - | - | 4,122 | Feb 5, 2026 |
| Oct 22, 2025 | Slanix Paul Alex director | AGrant or award Option (right to buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Oct 24, 2025 |
| Oct 3, 2025 | Max A. Milbury Principal Accounting Officer | POpen-market purchase Common Shares | +30,392 | $0.49 | $15k | 45,389 | Oct 6, 2025 |
| Jul 25, 2025 | Jeremy M. Sclar 2012 Irrevocable Family Trust owner | XIn-the-money exercise Common Shares, no par value | +697,674 | - | - | 2,315,111 | Sep 30, 2025 |
| Jul 25, 2025 | Jeremy M. Sclar 2012 Irrevocable Family Trust owner | XIn-the-money exercise Common Shares, no par value | +697,674 | - | - | 3,012,785 | Sep 30, 2025 |
| Jul 25, 2025 | Jeremy M. Sclar 2012 Irrevocable Family Trust owner | XIn-the-money exercise Common Shares, no par value | +697,674 | - | - | 3,710,459 | Sep 30, 2025 |
| Jul 25, 2025 | Jeremy M. Sclar 2012 Irrevocable Family Trust owner | XIn-the-money exercise Tranche A Common Share Purchase Warrantsderivative | -697,674 | $0.00 | $0 | 0 | Sep 30, 2025 |
| Jul 25, 2025 | Jeremy M. Sclar 2012 Irrevocable Family Trust owner | XIn-the-money exercise Tranche B Common Share Purchase Warrantsderivative | -697,674 | $0.00 | $0 | 0 | Sep 30, 2025 |
| Jul 25, 2025 | Jeremy M. Sclar 2012 Irrevocable Family Trust owner | XIn-the-money exercise Tranche C Common Share Purchase Warrantsderivative | -697,674 | $0.00 | $0 | 0 | Sep 30, 2025 |
| Jul 29, 2025 | Jeremy M. Sclar 2012 Irrevocable Family Trust owner | POpen-market purchase Warrant to Purchase Common Sharesderivative | +3,139,533 | - | - | 3,139,533 | Sep 30, 2025 |
| Sep 22, 2025 | Neil Cashman Chief Scientific Officer | AGrant or award Option (right to buy)derivative | +165,000 | $0.00 | $0 | 165,000 | Sep 24, 2025 |
| Sep 22, 2025 | Larry Douglas Altstiel Chief Medical Officer | AGrant or award Option (right to buy)derivative | +165,000 | $0.00 | $0 | 165,000 | Sep 24, 2025 |
| Sep 22, 2025 | Johanne Kaplan Chief Development Officer | AGrant or award Option (right to buy)derivative | +165,000 | $0.00 | $0 | 165,000 | Sep 24, 2025 |
| Sep 22, 2025 | Max A. Milbury Principal Accounting Officer | AGrant or award Option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Sep 24, 2025 |
| Sep 22, 2025 | Neil K Warma Chief Executive Officer | AGrant or award Option (right to buy)derivative | +600,000 | $0.00 | $0 | 600,000 | Sep 24, 2025 |
| Jul 25, 2025 | Jeremy M. Sclar owner | XIn-the-money exercise Common Shares, no par valueindirect: By: Jeremy M. Sclar 2012 Irrevocable Family Trust | +697,674 | - | - | 2,315,111 | Sep 8, 2025 |
| Jul 25, 2025 | Jeremy M. Sclar owner | XIn-the-money exercise Common Shares, no par valueindirect: By JS Trust | +697,674 | - | - | 3,012,785 | Sep 8, 2025 |
| Jul 25, 2025 | Jeremy M. Sclar owner | XIn-the-money exercise Common Shares, no par valueindirect: By JS Trust | +697,674 | - | - | 3,710,459 | Sep 8, 2025 |
| Jul 25, 2025 | Jeremy M. Sclar owner | XIn-the-money exercise Tranche A Common Share Purchase Warrantsderivativeindirect: See footnote | -697,674 | $0.00 | $0 | 0 | Sep 8, 2025 |
| Jul 25, 2025 | Jeremy M. Sclar owner | XIn-the-money exercise Tranche B Common Share Purchase Warrantsderivativeindirect: See footnote | -697,674 | $0.00 | $0 | 0 | Sep 8, 2025 |
| Jul 25, 2025 | Jeremy M. Sclar owner | XIn-the-money exercise Tranche C Common Share Purchase Warrantsderivativeindirect: See footnote | -697,674 | $0.00 | $0 | 0 | Sep 8, 2025 |
| Jul 29, 2025 | Jeremy M. Sclar owner | POpen-market purchase Warrant to Purchase Common Sharesderivativeindirect: See footnote | +3,139,533 | - | - | 3,139,533 | Sep 8, 2025 |
| Jul 25, 2025 | Michael S Gordon other | XIn-the-money exercise Tranche A Common Share Purchase Warrantsderivativeindirect: See footnote | -119,800 | $0.00 | $0 | 345,316 | Aug 14, 2025 |
| Jul 25, 2025 | Title 19 Promis other | XIn-the-money exercise Tranche A Common Share Purchase Warrantsderivative | -119,800 | $0.00 | $0 | 345,316 | Aug 14, 2025 |
| Mar 13, 2025 | Michael S Gordon other | JOther Common Shares, no par valueindirect: By Title 19 Acies | -48,333 | - | - | 0 | Aug 14, 2025 |
| Jul 25, 2025 | Title 19 Promis other | XIn-the-money exercise Tranche B Common Share Purchase Warrantsderivative | -119,800 | $0.00 | $0 | 345,316 | Aug 14, 2025 |
| Jul 25, 2025 | Michael S Gordon other | XIn-the-money exercise Tranche B Common Share Purchase Warrantsderivativeindirect: See footnote | -119,800 | $0.00 | $0 | 345,316 | Aug 14, 2025 |
| Jul 25, 2025 | Title 19 Promis other | XIn-the-money exercise Tranche C Common Share Purchase Warrantsderivative | -119,800 | $0.00 | $0 | 345,316 | Aug 14, 2025 |
| Jul 25, 2025 | Michael S Gordon other | XIn-the-money exercise Tranche C Common Share Purchase Warrantsderivativeindirect: See footnote | -119,800 | $0.00 | $0 | 345,316 | Aug 14, 2025 |
| Jul 25, 2025 | Michael S Gordon owner | XIn-the-money exercise Common Shares, no par valueindirect: By Title 19 Promis | +119,800 | - | - | 2,195,429 | Jul 29, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Larry Douglas AltstielChief Medical Officer
- Slanix Paul Alexdirector
- Neil CashmanChief Scientific Officer
- Michael S Gordonowner, other
- Jeremy M. Sclar 2012 Irrevocable Family Trustowner
- Johanne KaplanChief Development Officer
- Patrick D. Kirwindirector
- Max A. MilburyPrincipal Accounting Officer
- Ivana RubinoChief Commercial Officer
- Jeremy M. Sclarowner
- Title 19 Promisowner, other
- Neil K WarmaChief Executive Officer
- Eugene Williamsdirector
Questions about PMN
Answered from the filings on this page, as of the latest one.
Are insiders buying PMN?
No. In the last 90 days no insider at ProMIS Neurosciences Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade PMN on the open market?
Eugene Williams (director) bought $49k of PMN on Mar 5, 2026 and filed the Form 4 on Mar 6, 2026. InsiderTell scored 38 (weak), with 2 insiders on the same side within 14 days.
How many insiders file Form 4 at ProMIS Neurosciences Inc.?
13 people have filed a Form 4 at ProMIS Neurosciences Inc., among them Larry Douglas Altstiel (Chief Medical Officer), Slanix Paul Alex (director), Neil Cashman (Chief Scientific Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.